Cost Is the Biggest Barrier to Growth Hormone Adherence

You've diagnosed growth hormone deficiency, confirmed it with provocative testing, fought through the prior authorization process, and finally gotten your patient started on Saizen (Somatropin). Then they stop filling their prescription because they can't afford it.

This scenario plays out constantly in endocrinology practices. Growth hormone therapy is among the most expensive chronic medication categories in the United States, and Saizen is no exception — with monthly costs ranging from $800 to $3,000+ depending on dose and insurance coverage. Even patients with commercial insurance can face co-pays of hundreds of dollars per month for specialty tier medications.

As a provider, you're not a financial counselor. But knowing what resources exist — and building cost conversations into your workflow — can be the difference between a patient who stays on therapy and one who silently stops.

This guide covers the savings programs, alternatives, and workflow strategies that can help your patients afford their Saizen prescriptions.

What Your Patients Are Actually Paying

Understanding the cost landscape helps you have informed conversations:

• Cash price (no insurance): $700-$1,500+ per vial. The 5 mg vial runs approximately $737-$900; the 8.8 mg vial runs $1,150-$1,500.
• Monthly cost: $800-$3,000+ depending on dose, with adult patients on higher doses paying toward the upper end.
• With insurance: Varies widely. Specialty tier co-pays can range from $50-$500+ per month depending on the plan. Many plans have separate specialty pharmacy co-pay structures.
• With GoodRx or discount cards: Prices may start around $287, though availability at this price is limited.
• Biosimilar alternative (Omnitrope): Typically $500-$900/month, offering meaningful savings for some patients.

The patients most at risk for non-adherence due to cost are those in the "coverage gap" — they have insurance but with high deductibles or specialty tier co-pays that make each refill a financial decision.

Manufacturer Savings Programs

EMD Serono Patient Support Programs

EMD Serono, the manufacturer of Saizen, offers several support programs through their website at emdserono.com:

• Co-pay assistance program — Available for commercially insured patients. Can significantly reduce out-of-pocket costs per fill. Patients must have commercial insurance (not Medicare, Medicaid, or other government programs).
• Patient assistance program (PAP) — Provides free Saizen to qualifying uninsured or underinsured patients who meet income requirements. Requires application and documentation.
• Patient support line — Dedicated representatives can help navigate insurance issues, prior authorizations, and connect patients with appropriate programs.

Clinical tip: Have your front desk or care coordinator keep EMD Serono's patient support number accessible. A quick referral call at the time of prescribing can connect patients to resources before cost becomes a barrier.

Prescription Hope

Prescription Hope is a national organization that works with pharmaceutical manufacturers to provide medications at a flat rate. They offer Saizen for $70/month for qualifying patients. This can be a significant option for patients who don't qualify for manufacturer PAPs but still struggle with costs.

Coupon and Discount Card Programs

For patients paying cash or facing high co-pays, discount programs can provide meaningful relief:

• GoodRx — Lists Saizen pricing at various pharmacies with coupon codes. While specialty pharmacies may not always accept these, it's worth checking.
• SingleCare — Another discount card option that may offer savings at participating pharmacies.
• RxAssist — A comprehensive database of patient assistance programs, including manufacturer programs, state programs, and foundation grants.
• NeedyMeds — Lists assistance programs and discount drug cards. Can be particularly helpful for identifying programs patients might not find on their own.

Important caveat: Discount cards and co-pay coupons generally cannot be used with Medicare, Medicaid, or other federal healthcare programs. Patients on these programs should be directed to manufacturer PAPs or state pharmaceutical assistance programs instead.

Generic Alternatives and Therapeutic Substitution

There is no true generic version of Saizen. However, several options may reduce costs:

Biosimilar: Omnitrope

Omnitrope (Sandoz) was the first biosimilar growth hormone approved in the United States in 2006. It contains the same Somatropin molecule and is approved for the same indications. Key considerations:

• Typically costs $500-$900/month, representing meaningful savings over Saizen
• Available in both vials and pen cartridges
• Many insurance plans prefer Omnitrope as the first-line growth hormone product
• Clinically equivalent efficacy and safety profile

Preferred Brand Switching

Insurance formularies increasingly designate specific growth hormone brands as preferred. Common preferred products include:

• Norditropin (Novo Nordisk) — Pre-filled FlexPro pens, often preferred by multiple commercial payers
• Genotropin (Pfizer) — GoQuick pens and MiniQuick single-use devices
• Omnitrope (Sandoz) — Often the lowest-tier option on formularies

If a patient's insurance doesn't cover Saizen or places it on a non-preferred tier, switching to a formulary-preferred brand can dramatically reduce costs while delivering the same active ingredient. Before switching, check the patient's specific plan formulary and prior authorization requirements.

When Therapeutic Substitution Makes Sense

Since all approved Somatropin products contain the same molecule and work through the same mechanism, therapeutic substitution between brands is clinically straightforward. Consider switching when:

• The patient's insurance doesn't cover Saizen or requires excessive cost-sharing
• A formulary change moves Saizen to a higher tier
• The patient's co-pay for Saizen exceeds their budget
• Supply chain issues affect Saizen availability (see our provider shortage update)

The main adjustments when switching are injection technique training (different devices) and re-titration of the dose based on IGF-1 monitoring. For a clinical comparison of alternatives, see our article on alternatives to Saizen.

Building Cost Conversations into Your Workflow

The most effective savings strategy isn't any single program — it's making cost a standard part of your clinical workflow. Here's how to integrate it:

At the Time of Prescribing

1. Check the formulary first — Before writing for Saizen specifically, check whether the patient's plan has a preferred growth hormone product. Starting with the preferred brand avoids step therapy delays and reduces cost.
2. Discuss cost proactively — Don't assume patients will bring up cost concerns. Many won't, and they'll simply not fill the prescription. A brief statement like "Growth hormone therapy can be expensive — let's make sure we connect you with savings resources" opens the door.
3. Refer to patient support — Connect patients with EMD Serono's support program (or the relevant manufacturer) at the time of prescribing, not after they've already experienced sticker shock at the pharmacy.

At Follow-Up Visits

1. Ask about adherence and cost — "Have you been able to fill your Saizen prescriptions regularly?" can reveal cost barriers patients haven't volunteered.
2. Monitor for coverage changes — Insurance formularies change annually. A medication that was covered last year may have moved tiers or been dropped.
3. Reassess the savings program landscape — New programs and eligibility changes occur regularly. A quick check can identify new options.

Leverage Your Team

• Train medical assistants and care coordinators to hand patients savings program information at the time of prescribing
• Keep a resource sheet with current manufacturer program phone numbers, discount card websites, and PAP application links
• Use specialty pharmacy liaisons — Most specialty pharmacies have financial coordinators who can help patients identify coverage options

Quick-Reference: Saizen Savings Resources

• EMD Serono Patient Support: emdserono.com
• Prescription Hope: $70/month for qualifying patients
• NeedyMeds: needymeds.org
• RxAssist: rxassist.org
• GoodRx: goodrx.com
• Medfinder (for providers): medfinder.com/providers — Help patients find pharmacies with Saizen in stock

Final Thoughts

Growth hormone deficiency doesn't resolve itself, and treatment works only when patients can consistently access their medication. The $800-$3,000+ monthly price tag for Saizen means that cost will be a conversation — whether you initiate it or it happens silently when patients stop filling prescriptions.

By knowing what programs exist, checking formularies before prescribing, and building cost discussions into your workflow, you can help more patients stay on therapy and achieve the outcomes that led you to prescribe growth hormone in the first place.

For more provider resources on growth hormone therapy, see our guides on helping patients find Saizen in stock and the Saizen shortage from a provider perspective. And visit Medfinder for Providers to explore tools that can help your practice support patients with specialty medication access.